SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : H&Q Conference, January Effect, Etc.
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: damniseedemons who wrote (84)1/9/1997 12:23:00 PM
From: Giuseppe Scalamogna   of 246
 
Sal,

The short-term run up in NXCO I think is of little importance here. This company has a drug which could in most circumstances replace morphine as a severe pain killer. The market for this drug is huge and I think this company's growth potential isn't priced into it because we may go a little while before we get to and through Phase III trials and the drug gets approved. On top of that, this company will start seeing some nice earnings in the meantime as Corlopam hits the drug community.

I see a similar scenario unfolding for GZTC. They have moved into phase II trials of their human antithrombin III (ATIII), a plasma protein that helps prevent blood clotting in many medical conditions, and have already secured an agreement with BASF to produce showing that the pharmaceutical industry has shown interest in GZTC's transgenic production of proteins and molecular substances as a viable alternative to current mass production methods. If ATIII goes well, they will have a sales base from which to market other transgenic products in the future. I see major growth for this company in the future. Right now I'm not trading on technicalities because although hedging against some risk and picking it up at a better price, I don't think it much affects the bigger picture.

Regards,

Giuseppe Scalamogna
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News